Cytochrome P450 2D6

Layman’s Synopsis of 2D6 & lack of that pathway in some leading to disaster

National Coalition of Organized Women
From Laboring Women to Labor Unions, We Move as One

From the desk of the Director:                           2011
An argument for genetic testing in mental illness as “Standard of Care”:
Toxic Sensitivity Behavior Performance (TSBP) or the more dangerous Iatrogenic Sociopathic Syndrome (ISS) induced by a physician, by medical treatment or diagnostic procedures puts the public at great risk.  Homicides, school shootings, random acts of violence, mental illness and suicides are on a meteoric rise since the introduction of anti depressants, SSRIs and other modern psyche drugs.
An “inadvertent” induction of TSBP or ISS by a psychiatrist can no longer serve as a credible or legal excuse for iatrogenic harm to the patient and safety risk to the public at large considering the wealth of research, science-based evidence and clinical reports since the mapping of genes and the identification of GENETIC POLYMORPHISMS OF CYTOCHROME P450 (CYP) 2D6 and other alleles since the 1980s.
An efficient 2D6 metabolic pathway is required in order to metabolize more than 25% of all psyche drugs. Polymorphism of cytochrome P450 is significant in the population. As much as 7-10% of Caucasians, for example, are poor metabolizers or absent 2D6; 20% of Tanzanian Africans.  A limited demographic chart can be found at .  A list of the drugs that need the 2D6 and other alleles can be found
More frequently pharmaceutical manufacturers are being sued, settling cases and paying out millions of dollars for Failure To Warn.  For example, it was successfully argued that the Eli Lilly Company failed to publicize research showing some people are “poor metabolizers of Prozac” while a test can reveal if a patient might be affected. Cassidy vs. Eli Lilly, 2002
Soon Hospitals and Psychiatrists will join the ranks of failed defendants, as medical malpractice attorneys become educated in the subject of gene testing and psychiatry, thereby opening up channels for multiple level litigations.   Due to the ever expanding field of pharmacogenetics, and the ever increasing inclusion of information on Cytochrome P450 in manufacturers’ package inserts, (specifically information on 2D6) there is no question that psychiatric directors of hospitals, mental health clinics directors and psychiatrists in general have working knowledge and have, indeed, had sufficient knowledge of genetic polymorphism of Cytochrome P450 2D6 and other alleles for the past 10-15 years.  Clearly disregarding this knowledge, psychiatrists have “failed to warn” their patients putting them in harms way and the public at great risk.
Eileen Dannemann